Corbus Pharmaceuticals Holdings, Inc.
CRBP
NASDAQ·Healthcare·Biotechnology·Mkt cap $205.3M
$11.08
▼ -3.32%
P/E
-1.79
Mkt Cap
$205.3M
52-Wk Range
$7.12–$20.56
52-Week Range
$7.12 - $20.56
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CB2 agonist technology with selective immune modulation capabilities
- Diverse pipeline addressing multiple high-impact therapeutic areas with unmet medical needs
- Access to Jenrin Discovery's library of ~600 compounds expanding development opportunities
- Strong patent portfolio with multiple issued and pending patent filings protecting intellectual property
Bear Case
1 risk
- High volatility (beta 2.6). Larger-than-normal price swings expected.
Growth
Stable outlook
Phase II clinical trial advancement for lenabasum in systemic lupus erythematosus
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+46.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRBP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 6, 2026
Reported EPS of -$1.81 vs -$1.26 consensus (-43.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-43.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 26, 2026
vs Industry
How CRBP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related